Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Therapy with RV4104A and Ciclopirox vs Amorolfine for Onychomycosis
NCT01014637Phase 4Unknown
- Sponsor
- Pierre Fabre Laboratories
- Start
- Aug 2009
- Primary completion
- Sep 2011
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of RV4104A, ciclopirox in onychomycosis, sponsored by Pierre Fabre Laboratories. Status: unknown.
02
Drugs
RV4104Aciclopirox
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT01014637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01014637.